# Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers

> **NCT06800612** · — · RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer Metastatic
- Ovarian Cancer
- Cervical Carcinoma
- Endometrial Cancer

## Interventions

- **DRUG:** Oncologic drugs administered for treatment of breast cancer
- **DRUG:** Oncologic drug administered for treatment of gynecologic cancer

## Key facts

- **NCT ID:** NCT06800612
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-22
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06800612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06800612, "Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06800612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*